The invention relates to a first composition providing at least one of acetic acid or butyric acid for controlling ketosis associated with a ketogenic diet in a subject adhering to a ketogenic diet, wherein controlling ketosis involves a) administering the first composition, b) optionally administering a second composition comprising propionic acid to reduce ketone production/administering a second composition comprising propionic acid provided that blood ketone levels are above 3 mmol/L.
A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
A61K 31/455 - Nicotinic acid, i.e. niacin; Derivatives thereof, e.g. esters, amides
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 47/36 - Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
The invention relates to at least one of C4 or C6 fatty acids and optionally C2 fatty acids for enhancing ketosis associated with a ketogenic diet and/or preventing and/or treating resistance to a ketogenic diet, in a subject adhering to a ketogenic diet, wherein the at least one of C4 or C6 fatty acids and optionally C2 fatty acids are comprised in a non-ketogenic ketogenic diet-booster composition, or the at least C4 or C6 fatty acids and optionally C2 fatty acids are provided in non-ketogenic amounts by a dietary fibre blend comprised in a non-ketogenic ketogenic diet-booster composition.
Provided herein is a nutritional composition having therapeutically effective amounts of a combination of (a) hydrolysed whey protein and (b) MCT for use in (i) reducing tumor growth and/or (ii) for use in improving treatment efficacy in a subject having cancer and undergoing cancer treatment.
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
The invention provides a method, system, and computer program product for determining a maturation state of an infant aged between 0 and 120 months, comprising
The invention provides a method, system, and computer program product for determining a maturation state of an infant aged between 0 and 120 months, comprising
measuring at least one microbial biomarker from a set of measurable microbial biomarkers from a faecal sample of the infant,
The invention provides a method, system, and computer program product for determining a maturation state of an infant aged between 0 and 120 months, comprising
measuring at least one microbial biomarker from a set of measurable microbial biomarkers from a faecal sample of the infant,
determining a predicted age of the infant based on the at least one microbial biomarker,
The invention provides a method, system, and computer program product for determining a maturation state of an infant aged between 0 and 120 months, comprising
measuring at least one microbial biomarker from a set of measurable microbial biomarkers from a faecal sample of the infant,
determining a predicted age of the infant based on the at least one microbial biomarker,
wherein
The invention provides a method, system, and computer program product for determining a maturation state of an infant aged between 0 and 120 months, comprising
measuring at least one microbial biomarker from a set of measurable microbial biomarkers from a faecal sample of the infant,
determining a predicted age of the infant based on the at least one microbial biomarker,
wherein
the at least one microbial biomarker is selected from the set of measurable microbial biomarkers based on an analysis of the set of measurable microbial biomarkers as measured in faecal samples from a plurality of vaginally-born breast-fed infants at a plurality of ages,
The invention provides a method, system, and computer program product for determining a maturation state of an infant aged between 0 and 120 months, comprising
measuring at least one microbial biomarker from a set of measurable microbial biomarkers from a faecal sample of the infant,
determining a predicted age of the infant based on the at least one microbial biomarker,
wherein
the at least one microbial biomarker is selected from the set of measurable microbial biomarkers based on an analysis of the set of measurable microbial biomarkers as measured in faecal samples from a plurality of vaginally-born breast-fed infants at a plurality of ages,
the predicted age is obtained based on an evaluation of the at least one measured microbial biomarker using a function based on a plurality of corresponding at least one biomarkers measured in the faecal samples from the plurality of vaginally-born breast-fed infants at the plurality of ages.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16B 25/10 - Gene or protein expression profiling; Expression-ratio estimation or normalisation
5.
NUTRITIONAL COMPOSITION COMPRISING UREA, NON-DIGESTIBLE OLIGOSACCHARIDE, AND BIFIDOBACTERIA
The invention relates to nutritional compositions for infants and in particular formulae for infants comprising human milk oligosaccharides, specific bifidobacteria, and urea as non-protein nitrogen source for improving the intestinal microbiota.
The invention relates to a nutritional composition comprising a combination of (i) omega-3 fatty acid DHA with (ii) vitamin B2 and (iii) vitamin D3 and one or more from (iv) choline or a salt thereof and/or choline esters; and (v) dietary fibres and/or dietary butyrate for use in the treatment of neurodegenerative diseases and/or neurotrauma, brain injury and/or brain damage. The invention also relates to a composition comprising a combination of DHA, vitamin B2, vitamin D3 with one or more from (iv) choline or a salt thereof and/or choline esters; and (v) dietary fibres and/or dietary butyrate.
A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
A61P 25/00 - Drugs for disorders of the nervous system
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61L 33/00 - Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
7.
FERMENTED FORMULA WITH NON DIGESTIBLE OLIGOSACCHARIDES
The present invention relates to a fermented infant or follow on formula comprising non digestible oligosaccharides for decreasing duration of crying, reducing crying episodes, and incidence of colics in infants.
The invention relates to a neuroprotective composition comprising therapeutically effective amounts of a combination of pyruvate and citrate, for the treatment and/or prevention of neuronal damage in a subject suffering from or at risk of seizures.
A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61P 25/00 - Drugs for disorders of the nervous system
9.
Method and system for characterizing stool patterns of young infants
The invention provides a method of analysing the consistency of stool, including the steps of: providing stool of an infant, capturing, with a portable device comprising a camera, an image of the stool, providing the captured image to an input layer of a pre-trained convolutional neural network, CNN, processing the captured image using the CNN to obtain, from a final layer of the CNN, a classification vector and to obtain information about a predicted score from the classification vector, wherein at least the final layer of the CNN has been customized so that each element of the classification vector corresponds to a score of a stool analysis scale, and storing information about the predicted store.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
10.
AMINO ACID METABOLITES FOR ENHANCED DETOXIFICATION ACTIVITY
The invention pertains to a method for increasing and/or improving detoxification capacity comprising increasing AhR activity and/or increasing expression of CYP1A1 in a human subject comprising administering a combination of indole lactic acid (ILA) and imidazole lactic acid (IML), therapeutically effective combinations of ILA and IML for use in improving detoxification and a nutritional composition that comprises ILA and IML for use in improving detoxification.
The present invention relates to a nutritional composition for infants and young children comprising a digestible carbohydrate component, wherein the digestible carbohydrate component comprises a mixture of free galactose and at least one digestible carbohydrate selected from the group consisting of maltodextrin and glucose syrup, and with reduced or no lactose and glucose. The invention also relates to the use of the nutritional composition according to the invention for improving body composition or body composition development.
The invention relates to a process for dephosphorylation of skim milk, ultra-filtered milk (UF milk) or micellar casein isolate (MCI) comprising (i) acidification of a skim milk, UF milk or MCI preferably not lower than pH 6.0, preferably between 6.0 and 6.7, (ii) cooling the acidified skim milk, UF milk or MCI to the temperature between 0 °C and 15°C, (iii) adding gluconate and/or maleate to the cooled skim milk, UF milk or MCI and, (iv) washing the skim milk, UF milk or MCI, to remove phosphorus, thus dephosphorylating the skim milk, UF milk or MCI, preferably to an extent that the total phosphorous content of the skim milk, UF milk or MCI is reduced with at least 20%, preferably 20-40%, more preferably 30 – 40 % compared to the material provided to step (i). The invention also relates to dephosphorylated MPC, MPI or MCI obtainable by the process of the invention, and to a liquid heat- sterilized enteral nutritional composition comprising 2.0 – 3.0 kcal/ml wherein 16 – 35 en% is provided by protein, the combination of caloric content and relative protein caloric content selected such that there is 10 – 18 g/100 ml protein, preferably 12 – 18 g/100 ml protein in the composition, wherein the protein comprises micellar casein (MC), whey protein (WP) and optionally caseinate (CAS), wherein there is at least 70 wt % MC and less than 15 wt % WP, based on total protein content, and wherein the composition has a total amount of phosphorous less than 192 mg/100 ml and/or 30 – 80 mg/100kcal, preferably at least 30 – 80 mg/100 kcal, most preferably less than 192 mg/100 ml and 30 – 80 mg/100kcal.
The invention relates to a process for dephosphorylation of skim milk, ultra-filtered milk (UF milk) or micellar casein isolate (MCI) comprising (i) acidification of a skim milk, UF milk or MCI preferably not lower than pH 6.0, preferably between 6.0 and 6.7, (ii) cooling the acidified skim milk, UF milk or MCI to the temperature between 0 °C and 15°C, (iii) adding gluconate and/or maleate to the cooled skim milk, UF milk or MCI and, (iv) washing the skim milk, UF milk or MCI, to remove phosphorus, thus dephosphorylating the skim milk, UF milk or MCI, preferably to an extent that the total phosphorous content of the skim milk, UF milk or MCI is reduced with at least 20%, preferably 20-40%, more preferably 30 - 40 % compared to the material provided to step (i). The invention also relates to dephosphorylated skim milk, UF milk or MCI obtainable by the process of the invention, and to a liquid heat-sterilized enteral nutritional composition comprising 2.0 - 3.0 kcal/ml wherein 16 - 35 en % is provided by protein, the combination of caloric content and relative protein caloric content selected such that there is 10 - 18 g/100 ml protein, preferably 12 - 18 g/100 ml protein in the composition, wherein the protein comprises micellar casein (MC), whey protein (WP) and optionally caseinate (CAS), wherein there is at least 70 wt % MC and less than 15 wt % WP, based on total protein content, and wherein the composition has a total amount of phosphorous less than 192 mg/100 ml and/or 30 - 80 mg/100kcal, preferably at least 30 - 80 mg/100 kcal, most preferably less than 192 mg/100 ml and 30 - 80 mg/100kcal.
The present invention concerns a powdered nutritional composition comprising dairy protein and plant-based protein with improved organoleptic properties and flowability, a dry-blending process for obtaining the nutritional composition and a method for providing nutrition to a subject comprising administering the nutritional composition. The nutritional compositions according to the invention have an improved flowability index and improved organoleptic properties.
A23C 9/18 - Milk in dried and compressed or semi-solid form
A23C 11/06 - Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing non-milk proteins
The present invention relates to a method of fortifying human nutrition with free amide containing amino acids, a method of providing infant nutrition to an infant of a lactating woman that suffers from allergy or of a lactating woman that has suffered from allergy, and supplements or fortified infant formulas comprising free L-glutamine and/or free L-asparagine for use in the treatment or prevention of allergy in infants of a lactating woman that suffers from allergy or of a lactating woman that has suffered from allergy.
A lid structure (10) for a container (40) comprises an annular collar (14) for attachment to the container, having an opening (15) for providing access to an interior (56) of the container. The lid structure further comprises a lid (12) for closing the opening, connected to the collar by a first living hinge. The lid comprises a first lid portion and a second lid portion connected together by a second living hinge which traverses the top surface of the lid and is parallel to the first living hinge. The first lid portion covers the opening. The second lid portion comprises a mating element and the collar comprises a complementary mating element, being configured to engage together to latch the lid to the collar in the closed position of the lid, whereby latching and unlatching of the lid structure is provided by a pivotable motion of the second lid portion about the second living hinge.
B65D 43/16 - Non-removable lids or covers hinged for upward or downward movement
B65D 43/22 - Devices for holding in closed position, e.g. clips
B65D 55/16 - Devices preventing loss of removable closure members
17.
METHOD FOR EXPANDING A CYLINDRICAL METALLIC PRECURSOR IN THE MANUFACTURE OF A THREE-PIECE CAN AND SHAPING MANDREL FOR EXPANDING A CYLINDRICAL METALLIC PRECURSOR
A method is described for expanding a cylindrical metallic precursor in the manufacture of a three-piece can. The method comprises the steps of: arranging the precursor, having an initial diameter, around a shaping mandrel, the shaping mandrel having a plurality of longitudinally extending segments disposed radially about a longitudinal axis of the shaping mandrel, the segments having arcuate surfaces for engaging an inner surface of the precursor wall; actuating, in a first step, a first subgroup of the plurality of segments to expand outwards to engage with the inner surface of the precursor wall and expand at least a portion of it to a first diameter that is larger than the initial diameter of the precursor; and actuating, in a second step, a second subgroup of the plurality of segments to expand outwards and also engage with the inner surface of the precursor wall whereby the second subgroup expands at least a portion of the precursor to a second diameter that is larger than the first diameter. The method allows a greater degree of expansion of the wall of a cylindrical metallic container, whereby greater variations in diameter can be achieved between recessed portions and the remainder of the wall.
B21D 51/26 - Making hollow objects characterised by the use of the objects cans or tins; Closing cans or tins in a permanent manner
B65D 8/00 - Containers having a curved cross-section formed by interconnecting or uniting two or more rigid, or substantially rigid, components made wholly or mainly of metal, plastics, wood or substitutes therefor
B65D 17/00 - Rigid or semi-rigid containers specially constructed to be opened by cutting or piercing, or by tearing of frangible members or portions
METHOD FOR EXPANDING A CYLINDRICAL METALLIC PRECURSOR IN THE MANUFACTURE OF A THREE-PIECE CAN AND SHAPING MANDREL FOR EXPANDING A CYLINDRICAL METALLIC PRECURSOR
A method is described for expanding a cylindrical metallic precursor in the manufacture of a three-piece can. The method comprises the steps of: arranging the precursor, having an initial diameter, around a shaping mandrel, the shaping mandrel having a plurality of longitudinally extending segments disposed radially about a longitudinal axis of the shaping mandrel, the segments having arcuate surfaces for engaging an inner surface of the precursor wall; actuating, in a first step, a first subgroup of the plurality of segments to expand outwards to engage with the inner surface of the precursor wall and expand at least a portion of it to a first diameter that is larger than the initial diameter of the precursor; and actuating, in a second step, a second subgroup of the plurality of segments to expand outwards and also engage with the inner surface of the precursor wall whereby the second subgroup expands at least a portion of the precursor to a second diameter that is larger than the first diameter. The method allows a greater degree of expansion of the wall of a cylindrical metallic container, whereby greater variations in diameter can be achieved between recessed portions and the remainder of the wall.
A lid structure (10) for a container (40) comprises an annular collar (14) for attachment to the container, having an opening (15) for providing access to an interior (56) of the container. The lid structure further comprises a lid (12) for closing the opening. The lid has an outer periphery (16) and an upper surface (18) with a circumferential ridge (20) located near to but spaced from the outer periphery, whereby a further container having a first base diameter (D1) can stack at an outside of the circumferential ridge. The circumferential ridge has at least two interruptions (22) dividing the circumferential ridge into at least two ridge portions (20A, B) whereby at least two further containers having the first base diameter can stack partially on the lid.
A lid structure (10) for a container (40) comprises an annular collar (14) for attachment to the container, having an opening (15) for providing access to an interior (56) of the container. The lid structure further comprises a lid (12) for closing the opening. The lid has an outer periphery (16) and an upper surface (18) with a circumferential ridge (20) located near to but spaced from the outer periphery, whereby a further container having a base diameter (dr) can stack at an outside of the circumferential ridge. The circumferential ridge has at least two interruptions (22) dividing the circumferential ridge into at least two ridge portions (20A, B) whereby at least two further containers having the same base diameter can stack partially on the lid.
The present invention concerns a powdered nutritional composition comprising intact protein and partially hydrolysed whey protein and a dry-blending process for obtaining the powdered nutritional composition.
A method performed by an electronic device assessing a first nutritional composition, obtaining (201, 301, 401) first visual information of the first nutritional composition; determining (202) whether there is a phase separation of the first nutritional composition based on the first visual information; if it is determined that there is a phase separation, determining (203) properties of at least one layer of the phase separation of the first nutritional composition based on the first visual information.
A consortium of specific probiotic bacteria comprising Bifidobacterium bifidum and Bifidobacterium breve with specific carbohydrate degrading properties, specific human milk oligosaccharide and preferably also beta-galacto-oligosaccharides with a higher degree of polymerization, is particularly effective for improving intestinal microbiota resilience.
The invention pertains to a solid composition suitable for treating adult animals that suffer from brain-related disorders, brain-related decline or brain-related diseases, preferably suitable for treating adult animals that suffer from brain-related disorders, the composition containing (i) a uridine source, wherein the amount of the sum of all uridine sources, calculated on the basis of the weight of the molar equivalent of uridine monophosphate (UMP), is 0.3-15 g per 100 g dry weight of the composition, (ii) a polyunsaturated fatty acid, preferably an omega-3 polyunsaturated fatty acid, (iii) choline bitartrate, (iv) a buffering salt component, and (v) a milk protein source, wherein the milk protein source is a milk powder, and the buffering salt component containing at least one food approved salt, with a buffering capacity between pH 5-8, the buffering salt component preferably containing a mixture of food-approved salts, or a food-approved salt and its conjugated acid or base.
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
The invention pertains to a liquid nutritional composition for use in prevention and/or treatment of whole body protein metabolism decline or whole body protein function decline, or for improving whole body protein metabolism or whole body protein function, particularly for use in muscle decline, or for improving muscle function, in a human subject suffering from metabolic stress and/or starvation, wherein the human subject is preferably a human elderly subject of at least 50 years of age, wherein the composition comprises a protein fraction comprising (a) 15 to 35 weight % of casein; (b) 25 to 50 weight % of whey protein; (c) 10 to 30 weight % of soy protein; and (d) 10 to 30 weight % of pea protein; relative to the total protein in the protein fraction, wherein the sum of said proteins preferably equals 100 weight % of the protein fraction.
Electronic device for estimating a height of a human, the electronic device comprising: a processor configured to: obtain an image including at least a part of a representation of the human and reference information; input the image to a first neural network and obtain as output from the first neural network first information, the first information related to a plurality of keypoints in the body of the human; input the image to a second neural network and obtain as output from the second neural network second information, the second information related to the reference information; and estimate the height of the human based on the first information and the second information; and an output unit configured to output the estimated height.
The invention concerns a process for preparing an ultrafiltered whey protein hydrolysate comprising tolerogenic peptides wherein an emulsifier and/or a chaotropic agent is added before ultrafiltration. The invention further concerns the product obtainable by the process.
A23C 9/142 - Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
A23C 21/02 - Whey; Whey preparations containing, or treated with, microorganisms or enzymes
A23C 21/08 - Whey; Whey preparations containing other organic additives, e.g. vegetable or animal products
Provided herein is an enteral ketogenic composition comprising (i) a lipid fraction comprising 45 to 65 g lipids, (ii) a carbohydrate fraction comprising 5 to 12 g digestible carbohydrates, and (iii) a protein fraction comprising 15 - 25 g of protein per 100g of the ketogenic composition, having a ketogenic weight ratio between 1.5:1 and 3.0:1 and therapeutic uses thereof.
A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
The present invention concerns nutritional compositions for infants and young children that are high in oleic acid and low in palmitic acid and comprise galacto-oligosaccharides, in particular including beta1,3′-galactosyllactose. The nutritional compositions are particularly advantageous for improving intestinal barrier function.
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
29 - Meat, dairy products, prepared or preserved foods
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Milk and milk products; yogurt; milk substitutes; plant-based milk and milk products, namely milks derived from plants, vegetables, grains, nuts, seeds, beans and fruits; cottage cheese; milk beverages, milk predominating; compotes; fruit-based snack foods; nut-based snack bars; seed-based snack bars; probiotic dairy-based snack bar; powdered milk; frozen, prepared, dried, preserved or packaged meals consisting primarily of meat, fish, poultry, ham, vegetables and game; yogurt-based snack foods; fruit purees Food for special medical purposes; dietetic foods and substances adapted for medical purposes; food for babies; food for patients and sick persons; infant formula; food for babies with special nutritional needs; non-dairy and plant-based milks for babies, namely milks derived from plants, vegetables, cereals, grains, nuts, seeds, beans and fruits; nutritional products for medical purposes; nutritional supplements; cereals for infants; vitamin preparations; dietetic foods for pregnant, lactating and breast feeding women; dietetic milk for pregnant, lactating and breast feeding women; dietary fiber; protein dietary supplements; soy protein dietary supplements; protein supplements shakes; energy bars used as food supplements; dietary supplements for human beings
31.
NUTRITIONAL COMPOSITION FOR MUSCLE MASS, STRENGTH AND FUNCTION
The invention pertains to a nutritional composition for use in prevention and/or treatment of whole body protein metabolism decline or whole body protein function decline, or for therapeutic use in improving whole body protein metabolism or whole body protein function, in a human subject, wherein the human subject is preferably an ageing human elderly subject of at least 40 years of age, wherein the composition comprises a protein fraction comprising 32-58 wt % pea protein, 30-56 wt % soy protein and 8-16 wt % free leucine, preferably a protein fraction comprising 36-54 wt % pea protein, 34-52 wt % soy protein and 10-14 wt % free leucine, and optionally up to 5 wt % of free branched chain amino acids other than leucine, based on all proteinaceous matter, wherein the composition is essentially free from animal protein.
The present invention relates to a use of octenylsuccinyl anhydride substituted starch (OSA starch) for increasing the dry weight content and/or the fat content of a liquid composition that is subjected to a spray-drying step, and also to a process for preparing powders. The present invention enables the spray-drying of emulsions that contain a high amount of fat. The present invention also relates to the powder products obtainable by the process and nutritional products such as an infant milk powder, grow up milk, toddler milk or as a medical nutritional product that can be formulated therewith.
A23P 10/47 - Making free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added using additives, e.g. emulsifiers, wetting agents or dust-binding agents
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 47/36 - Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
33.
NUTRITIONAL COMPOSITION WITH IMPROVED SEGREGATION RESISTANCE
The present invention relates to a powdered nutritional composition comprising (i) milk formula particles comprising lipid, protein, digestible carbohydrates, and (ii) human milk oligosaccharide (HMO) particles, wherein the nutritional composition is selected from an infant, follow-on formula and growing up milk, wherein said nutritional composition is not human milk and wherein the lipid in the milk formula particles is in the form of lipid globules, and a. the lipid globules have a mode diameter based on volume of at least 1 μm, and/or b. at least 40 vol.% of the lipid globules have a diameter of 2 to 12 μm and wherein the HMO particles comprise at least 2'fucosyllactose (2'FL). The invention also relates to a process to prepare the composition and uses thereof.
A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
The present invention concerns nutritional compositions comprising a mixture of non-digestible oligosaccharides consisting of a combination of 5 specific human milk oligosaccharides, beta-galacto-oligosaccharides and long chain fructo-oligosaccharides (IcFOS). The nutritional compositions are of benefit for improving intestinal microbiota.
The present invention relates to nutritional compositions comprising non-digestible oligosaccharides and beta-casein comprising at least 75% by weight of a beta-casein variant having a proline at position 67 of the beta-casein amino acid sequence for use in improving gut microbiota of an infant or child, wherein improvement of gut microbiota encompasses increasing Lactobacillus levels. Advantageously, the composition further favors the increase of Bifidobacterium levels and inhibits the growth of opportunistic and/or pathogenic bacteria.
A nutritional composition comprising digestible carbohydrates, protein and lipid, wherein the lipid is in the form of lipid globules which are at least partly coated on the surface with phospholipids, for improving the gut microbiota and reducing opportunistic pathogens in the gut of human infants.
The present invention relates to the field of infant nutrition. Particularly, the present invention relates to infant formula comprising human milk oligosaccharides wherein the infant formula is specific for infants aged 0-36 months at different lactation stages. The invention also relates to lactation stage specific systems and methods of providing nutrition to an infant.
The present invention relates to infant formula suitable for feeding infants who receive both infant formula and human breast milk (mixed milk fed infants).
A nutritional composition comprising digestible carbohydrates, protein and lipid, wherein the lipid is in the form of lipid globules which are at least partly coated on the surface with phospholipids, for increasing myelination in the brain of an infant who has delayed brain development or is at risk of having delayed brain development.
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
30 - Basic staples, tea, coffee, baked goods and confectionery
Goods & Services
(1) Food for special medical purposes; dietetic foods and substances adapted for medical purposes; food for babies; food for patients and sick persons; infant formula; food for babies with special nutritional needs; non-dairy and plant-based milks for babies, namely milks derived from plants, vegetables, cereals, grains, nuts, seeds, beans and fruits; nutritional products for medical purposes; nutritional supplements; cereals for infants; vitamin preparations; dietetic foods for pregnant, lactating and breast feeding women; dietetic milk for pregnant, lactating and breast feeding women; dietary fiber; protein dietary supplements; soy protein dietary supplements; protein supplements shakes; energy bars used as food supplements; dietary supplements for human beings.
(2) Milk and milk products; yogurt; milk substitutes; plant-based milk and milk products, namely milks derived from plants, vegetables, grains, nuts, seeds, beans and fruits; cottage cheese; milk beverages, milk predominating; compotes; fruit-based snack foods; nut-based snack bars; seed-based snack bars; probiotic dairy-based snack bar; powdered milk; frozen, prepared, dried, preserved or packaged meals consisting primarily of meat, fish, poultry, ham, vegetables and game; yogurt-based snack foods; fruit purees.
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
30 - Basic staples, tea, coffee, baked goods and confectionery
Goods & Services
(1) Food for special medical purposes; dietetic foods and substances adapted for medical purposes; food for babies; food for patients and sick persons; infant formula; food for babies with special nutritional needs; non-dairy and plant-based milks for babies, namely milks derived from plants, vegetables, cereals, grains, nuts, seeds, beans and fruits; nutritional products for medical purposes; nutritional supplements; cereals for infants; vitamin preparations; dietetic foods for pregnant, lactating and breast feeding women; dietetic milk for pregnant, lactating and breast feeding women; dietary fiber; protein dietary supplements; soy protein dietary supplements; protein supplements shakes; energy bars used as food supplements; dietary supplements for human beings.
(2) Milk and milk products; yogurt; milk substitutes; plant-based milk and milk products, namely milks derived from plants, vegetables, grains, nuts, seeds, beans and fruits; cottage cheese; milk beverages, milk predominating; compotes; fruit-based snack foods; nut-based snack bars; seed-based snack bars; probiotic dairy-based snack bar; powdered milk; frozen, prepared, dried, preserved or packaged meals consisting primarily of meat, fish, poultry, ham, vegetables and game; yogurt-based snack foods; fruit purees.
42.
NUTRITIONAL COMPOSITION FOR IMPROVING CELL MEMBRANES
An early in life nutritional intervention with a lipid component having both large lipid globules with phospholipids and an increased amount of palmitic acid in the sn-2 position in triglycerides were found to improve the fatty acid composition of cell membranes, in particular brain membranes.
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/688 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
A61P 25/00 - Drugs for disorders of the nervous system
29 - Meat, dairy products, prepared or preserved foods
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Milk and milk products; yogurt; milk substitutes; plant-based milk and milk products, namely milks derived from plants, vegetables, grains, nuts, seeds, beans and fruits; cottage cheese; milk beverages, milk predominating; compotes; fruit-based snack foods; nut-based snack bars; seed-based snack bars; probiotic dairy-based snack bar; powdered milk; frozen, prepared, dried, preserved or packaged meals consisting primarily of meat, fish, poultry, ham, vegetables and game; yogurt-based snack foods; fruit purees Food for special medical purposes; dietetic foods and substances adapted for medical purposes; food for babies; food for patients and sick persons; infant formula; food for babies with special nutritional needs; non-dairy and plant-based milks for babies, namely milks derived from plants, vegetables, cereals, grains, nuts, seeds, beans and fruits; nutritional products for medical purposes; nutritional supplements; cereals for infants; vitamin preparations; dietetic foods for pregnant, lactating and breast feeding women; dietetic milk for pregnant, lactating and breast feeding women; dietary fiber; protein dietary supplements; soy protein dietary supplements; protein supplements shakes; energy bars used as food supplements; dietary supplements for human beings
NUTRICIA EARLY LIFE NUTRITION (SHANGHAI) CO., LTD (China)
Inventor
Renes, Ingrid Brunhilde
Thomassen, Gabriel
Knol, Jan
Ludwig, Thomas
Jin, Haofang
Abstract
The present invention relates to compositions comprising lutein, non-digestible carbohydrates and at least one of casein phosphopetides or 1,3-dioleoyl-2-palmitoylglycerol.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Food for special medical purposes; dietetic foods and substances adapted for medical purposes; food for babies; food for patients and sick persons; infant formula; food for babies with special nutritional needs; non-dairy and plant-based milks for babies, namely milks derived from plants, vegetables, cereals, grains, nuts, seeds, beans and fruits; nutritional products for medical purposes; nutritional supplements; cereals for infants; vitamin preparations; dietetic foods for pregnant, lactating and breast feeding women; dietetic milk for pregnant, lactating and breast feeding women; dietary fiber; protein dietary supplements; soy protein dietary supplements; protein supplements shakes; energy bars used as food supplements; dietary supplements for human beings
46.
METHOD FOR SUPPORTING MEMORY FUNCTION AND/OR COGNITIVE FUNCTION
The invention pertains to the use of therapeutically effective amounts of (a) (i) vitamin C and/or selenium and (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; or (b) (i) vitamin C and/or selenium and (iii) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; or (c) a combination of (i), (ii) and (iii); wherein (a), (b) or (c) optionally further comprises vitamin E, in the manufacture of a product for therapeutically improving synaptic connectivity and/or therapeutically supporting memory and/or cognitive function in a human subject in need thereof.
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/375 - Ascorbic acid, i.e. vitamin C; Salts thereof
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
29 - Meat, dairy products, prepared or preserved foods
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Milk and milk products; yogurt; milk substitutes; plant-based milk and milk products, namely milks derived from plants, vegetables, grains, nuts, seeds, beans and fruits; cottage cheese; milk beverages, milk predominating; compotes; fruit-based snack foods; nut-based snack bars; seed-based snack bars; probiotic dairy-based snack bar; powdered milk; frozen, prepared, dried, preserved or packaged meals consisting primarily of meat, fish, poultry, ham, vegetables and game; yogurt-based snack foods; fruit purees Food for special medical purposes; dietetic foods and substances adapted for medical purposes; food for babies; food for patients and sick persons; infant formula; food for babies with special nutritional needs; non-dairy and plant-based milks for babies, namely milks derived from plants, vegetables, cereals, grains, nuts, seeds, beans and fruits; nutritional products for medical purposes; nutritional supplements; cereals for infants; vitamin preparations; dietetic foods for pregnant, lactating and breast feeding women; dietetic milk for pregnant, lactating and breast feeding women; dietary fiber; protein dietary supplements; soy protein dietary supplements; protein supplements shakes; energy bars used as food supplements; dietary supplements for human beings
The invention concerns formula for based on extensively hydrolysed protein and/or free amino acids for allergic infants that are thickened with a combination of xanthan gum and locust bean gum.
A23L 29/238 - Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
A23L 29/269 - Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
The invention is in the field of thickened formulas for infants that suffer from regurgitation. In particular the infant formulas are thickened with a combination of xanthan gum and locust bean gum and comprise a mixture of specific nondigestible oligosaccharides.
A23L 33/125 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing starch hydrolysates
A23L 29/238 - Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
A23L 29/269 - Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
The invention concerns formula for based on extensively hydrolysed protein and/or free amino acids for allergic infants that are thickened with a combination of xanthan gum and locust bean gum.
A23L 29/238 - Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
A23L 29/269 - Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A card-based package for sensitive food products, comprises a container portion defining an interior space with a base and a sidewall extending to an upper peripheral edge for receiving a removable seal for hermetically sealing the container portion prior to use. The package further comprises a lid structure, that can open and close to allow selective access to the interior space after removal of the seal. The container portion and the lid structure are both formed of card-based material and at least the container portion has light, oxygen, and water vapour barrier properties sufficient for storage of the product for a period exceeding 24 months.
B65D 3/22 - Rigid or semi-rigid containers having bodies or peripheral walls of curved or partially-curved cross-section made by winding or bending paper without folding along defined lines with walls made of laminated material
B65D 43/16 - Non-removable lids or covers hinged for upward or downward movement
A closure for an infant formula package is disclosed. The package may comprise a container having an access opening to an interior space, for receiving the infant formula. The closure is arranged for selectively closing the access opening and comprises a lid and a scoop holder located on an underside of the lid, wherein both the lid and the scoop holder are formed of card-based material.
A closure for an infant formula package is disclosed. The package may comprise a container having an access opening to an interior space, for receiving the infant formula. The closure is arranged for selectively closing the access opening and comprises a lid and a scoop holder located on an underside of the lid to retain a scoop, wherein the scoop holder comprises an apertured plate having an apertured portion with an aperture therethrough to receive at least part of the scoop, and wherein both the lid and the scoop holder are formed of card-based material.
A card-based package for powdered infant nutrition is described. The package comprises a container portion having an access opening to an interior space for receiving the powered infant nutrition and a closure arranged for selectively closing the access opening. The closure comprises a collar portion connected to the container portion, a lid portion pivotably connected to the collar portion and a locking arrangement for selectively engaging said lid portion to said collar portion. The container portion, the lid portion, the collar portion and the locking arrangement are all formed from card-based material. The locking arrangement comprises a first locking element arranged on the collar portion and a second locking element arranged on the lid portion wherein the first locking element and the second locking element are arranged to engage together to prevent the lid portion from being opened. One of the first or second locking elements is actionable by a user to disengage the other locking element and unlock the lid portion.
B65D 43/16 - Non-removable lids or covers hinged for upward or downward movement
B65D 3/26 - Opening arrangements or devices incorporated in, or attached to, containers
B65D 6/00 - Containers having bodies formed by interconnecting or uniting two or more rigid, or substantially rigid, components made wholly or mainly of metal, plastics, wood or substitutes therefor
B65D 21/02 - Containers specially shaped, or provided with fittings or attachments, to facilitate nesting, stacking, or joining together
B65D 51/20 - Caps, lids, or covers co-operating with an inner closure arranged to be opened by piercing, cutting, or tearing
B65D 77/24 - Inserts or accessories added or incorporated during filling of containers
55.
CARD BASED PACKAGE FOR POWDERED INFANT NUTRITION PRODUCTS
A card-based package for powdered infant nutrition, comprises a container portion, the container portion defining an interior space for receiving the powdered infant nutrition and having a base and a sidewall extending to an upper peripheral edge for receiving a removable seal for hermetically sealing the container portion prior to use. The package further comprises a collar portion and a lid portion. The collar portion is connected to and extends upwardly from the upper peripheral edge of the container portion and comprises a connection segment and an upper peripheral closure rim surrounding an access opening giving access to the interior space. The lid portion comprises a lid and a frame and forms a re-closable joint with the upper peripheral closure rim of the collar portion, allowing repeated and selective opening and closing of the access opening. The container portion, the collar portion and the lid portion all comprise card-based material.
B65D 3/26 - Opening arrangements or devices incorporated in, or attached to, containers
B65D 6/00 - Containers having bodies formed by interconnecting or uniting two or more rigid, or substantially rigid, components made wholly or mainly of metal, plastics, wood or substitutes therefor
B65D 21/02 - Containers specially shaped, or provided with fittings or attachments, to facilitate nesting, stacking, or joining together
B65D 43/16 - Non-removable lids or covers hinged for upward or downward movement
B65D 51/20 - Caps, lids, or covers co-operating with an inner closure arranged to be opened by piercing, cutting, or tearing
B65D 77/24 - Inserts or accessories added or incorporated during filling of containers
05 - Pharmaceutical, veterinary and sanitary products
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Food for special medical purposes; dietetic foods and
substances adapted for medical purposes; food for babies;
dietic food adapted for invalids; infant formula; food for
babies with special nutritional needs; non-dairy and
plant-based milks for babies, namely milks derived from
plants, vegetables, cereals, grains, nuts, seeds, beans and
fruits; nutritional products for medical purposes;
nutritional supplements; cereals for infants; vitamin
preparations; dietetic foods for pregnant, lactating and
breast feeding women; dietetic milk for pregnant, lactating
and breast feeding women; dietary fiber; protein dietary
supplements; soy protein dietary supplements; protein
supplements shakes; energy bars used as food supplements;
dietary supplements for human beings. Provision of training and information about it, in the
fields of preconception, pregnancy, birth, motherhood, baby
care, parenting and nutrition, for parents, mothers and
future parents, also via on-line connections; arranging,
organizing and conducting educational seminars and
conferences, including as provided by means of the internet,
in the fields of baby nutrition, food and drink, including
dietetic food and drink and food and drink adapted for
medical use, as well as in the fields of health, parenting,
personal hygiene, pregnancy, body and beauty care for
babies, infants and pregnant, lactating and breast feeding
women. Provision of advisory services and information in the field
of health care, nutrition and on hygienic and beauty care
for human beings, including advisory and information
services in relation to issues about preconception,
pregnancy, birth, motherhood, baby care and parenting, for
parents, mothers and future parents, also via on-line
connections; medical services; advisory, consultancy and
information services, including as provided by means of the
internet, in the fields of medicine, health care, baby
nutrition, personal hygiene, body and beauty care for babies
and infants, lactating and breast feeding women.
57.
CARD BASED PACKAGE FOR POWDERED INFANT NUTRITION PRODUCTS
A card-based package for powdered infant nutrition, comprises a container portion, the container portion defining an interior space for receiving the powdered infant nutrition and having a base and a sidewall extending to an upper peripheral edge for receiving a removable seal for hermetically sealing the container portion prior to use. The package further comprises a collar portion and a lid portion. The collar portion is connected to and extends upwardly from the upper peripheral edge of the container portion and comprises a connection segment and an upper peripheral closure rim surrounding an access opening giving access to the interior space. The lid portion comprises a lid and a frame and forms a re-closable joint with the upper peripheral closure rim of the collar portion, allowing repeated and selective opening and closing of the access opening. The container portion, the collar portion and the lid portion all comprise card-based material.
B65D 3/26 - Opening arrangements or devices incorporated in, or attached to, containers
B65D 6/00 - Containers having bodies formed by interconnecting or uniting two or more rigid, or substantially rigid, components made wholly or mainly of metal, plastics, wood or substitutes therefor
B65D 21/02 - Containers specially shaped, or provided with fittings or attachments, to facilitate nesting, stacking, or joining together
B65D 43/16 - Non-removable lids or covers hinged for upward or downward movement
B65D 51/20 - Caps, lids, or covers co-operating with an inner closure arranged to be opened by piercing, cutting, or tearing
B65D 77/24 - Inserts or accessories added or incorporated during filling of containers
A card-based package for powdered infant nutrition is described. The package comprises a container portion having an access opening to an interior space for receiving the powered infant nutrition and a closure arranged for selectively closing the access opening. The closure comprises a collar portion connected to the container portion, a lid portion pivotably connected to the collar portion and a locking arrangement for selectively engaging said lid portion to said collar portion. The container portion, the lid portion, the collar portion and the locking arrangement are all formed from card-based material. The locking arrangement comprises a first locking element arranged on the collar portion and a second locking element arranged on the lid portion wherein the first locking element and the second locking element are arranged to engage together to prevent the lid portion from being opened. One of the first or second locking elements is actionable by a user to disengage the other locking element and unlock the lid portion.
B65D 43/16 - Non-removable lids or covers hinged for upward or downward movement
B65D 3/26 - Opening arrangements or devices incorporated in, or attached to, containers
B65D 6/00 - Containers having bodies formed by interconnecting or uniting two or more rigid, or substantially rigid, components made wholly or mainly of metal, plastics, wood or substitutes therefor
B65D 21/02 - Containers specially shaped, or provided with fittings or attachments, to facilitate nesting, stacking, or joining together
B65D 51/20 - Caps, lids, or covers co-operating with an inner closure arranged to be opened by piercing, cutting, or tearing
B65D 77/24 - Inserts or accessories added or incorporated during filling of containers
A card-based package for sensitive food products, comprises a container portion defining an interior space with a base and a sidewall extending to an upper peripheral edge for receiving a removable seal for hermetically sealing the container portion prior to use. The package further comprises a lid structure, that can open and close to allow selective access to the interior space after removal of the seal. The container portion and the lid structure are both formed of card-based material and at least the container portion has light, oxygen, and water vapour barrier properties sufficient for storage of the product for a period exceeding 24 months.
B65D 3/22 - Rigid or semi-rigid containers having bodies or peripheral walls of curved or partially-curved cross-section made by winding or bending paper without folding along defined lines with walls made of laminated material
B65D 43/16 - Non-removable lids or covers hinged for upward or downward movement
60.
A PROCESS OF PREPARING AN ENTERAL NUTRITIONAL COMPOSITION
A process of preparing a shelf-stable liquid enteral nutritional composition, said process comprising the steps of providing an oil-in-water emulsion, sterilizing the emulsion by direct steam injection (DSI) to obtain a sterilized emulsion with a F0 value of at least 3 and subjecting the sterilized emulsion to high pressure homogenization.
A23L 3/3409 - Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of gases, e.g. fumigation; Compositions or apparatus therefor
A23L 5/30 - Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation
A23C 9/20 - Dietetic milk products not covered by groups
A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
A23C 11/00 - Milk substitutes, e.g. coffee whitener compositions
NUTRICIA EARLY LIFE NUTRITION (SHANGHAI) CO., LTD. (China)
Inventor
Ward, Gregg
Liu, Mengjin
Guo, Bingzhi
Jin, Yi
Zheng, Yixiao
Hu, Jinhui
Foussat, Agathe Camille
Song, Jiahang
Ludwig, Thomas
Abstract
A computer-implemented method of analyzing excreta, comprising: obtaining visual information of excreta, providing the visual information to an artificial intelligence (AI) model; processing the visual information using the AI model to determine a plurality of scales of the excreta; outputting the plurality of scales of the excreta, receiving at least one input to adjust the plurality of scales of the excreta, and providing suggestion based on the adjusted plurality of scales of the excreta.
NUTRICIA EARLY LIFE NUTRITION (SHANGHAI) CO., LTD. (China)
Inventor
Ward, Gregg
Liu, Mengjin
Guo, Bingzhi
Jin, Yi
Zheng, Yixiao
Hu, Jinhui
Foussat, Agathe Camille
Song, Jiahang
Ludwig, Thomas
Abstract
A computer-implemented method of analyzing excreta, comprising: obtaining visual information of excreta, providing the visual information to an artificial intelligence (AI) model; processing the visual information using the AI model to determine a plurality of scales of the excreta; outputting the plurality of scales of the excreta, receiving at least one input to adjust the plurality of scales of the excreta, and providing suggestion based on the adjusted plurality of scales of the excreta.
The invention pertains to a fiber mixture comprising arabinoxylan, beta-glucan, pectin, and resistant starch, nutritional compositions comprising the fiber mixture and uses thereof. The fiber mixture comprising is beneficially used in improving intestinal health and/or preventing impaired intestinal health.
A carrier for transport and administration of enteral food or other liquids comprises a shell, having a bottom tray, a back plate and two side plates and a front plate for attachment of a feed pump. Support elements are provided for holding a container in place within the shell. The support elements are height adjustable with respect to the bottom tray, thereby allowing a container to be supported at different positions above the bottom tray. The front plate is detachable from the shell and can be used as a stand for the feed pump. The carrier can be easily integrated into a backpack or the like.
A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes - Details; Accessories therefor
A61J 7/00 - Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
A61J 15/00 - Feeding-tubes for therapeutic purposes
A45C 11/00 - Receptacles for purposes not provided for in groups
A45C 13/02 - Interior fittings; Means for holding or packing articles
A carrier for transport and administration of enteral food or other liquids comprises a shell, having a bottom tray, a back plate and two side plates and a front plate for attachment of a feed pump. Support elements are provided for holding a container in place within the shell. The support elements are height adjustable with respect to the bottom tray, thereby allowing a container to be supported at different positions above the bottom tray. The front plate is detachable from the shell and can be used as a stand for the feed pump. The carrier can be easily integrated into a backpack or the like.
A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes - Details; Accessories therefor
A61J 7/00 - Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
A61J 15/00 - Feeding-tubes for therapeutic purposes
A45C 11/00 - Receptacles for purposes not provided for in groups
A45C 13/02 - Interior fittings; Means for holding or packing articles
The invention relates to a fibre mixture comprising beta-galactooligosaccharides, inulin, resistant starch and soluble soy polysaccharides and to nutritional compositions comprising such a fibre mixture. The intended use of the fibre mixture and nutritional compositions is for preventing or treating constipation, especially in young children.
A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
A61K 31/718 - Starch or degraded starch, e.g. amylose, amylopectin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
The present invention provides a process of producing a lactose concentrate, said process comprising the step of subjecting a partially demineralised aqueous lactose isolate to electrodialysis to produce a biotin-reduced lactose isolate containing at least 90% lactose by weight of dry matter and less than 2 mg ash per gram of lactose, and containing:
0.02-1.5 mg sodium per gram of lactose;
0.02-2 mg potassium per gram of lactose;
0.05-1.5 mg chloride per gram of lactose;
0.01-0.25 μg biotin per gram of lactose.
The present invention provides a process of producing a lactose concentrate, said process comprising the step of subjecting a partially demineralised aqueous lactose isolate to electrodialysis to produce a biotin-reduced lactose isolate containing at least 90% lactose by weight of dry matter and less than 2 mg ash per gram of lactose, and containing:
0.02-1.5 mg sodium per gram of lactose;
0.02-2 mg potassium per gram of lactose;
0.05-1.5 mg chloride per gram of lactose;
0.01-0.25 μg biotin per gram of lactose.
The present invention also relates to a demineralised lactose concentrate having a reduced biotin content that can be produced by the aforementioned process. The invention further relates to an oligosaccharide-enriched biotin-reduced fraction that is obtained when lactose is separated before or after the electrodialysis step.
A23C 9/144 - Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by electrical means, e.g. electrodialysis
A23C 9/142 - Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
A23L 33/125 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing starch hydrolysates
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
NUTRICIA EARLY LIFE NUTRITION (SHANGHAI) CO., LTD. (China)
Inventor
Renes, Ingrid Brunhilde
Thomassen, Gabriel
Knol, Jan
Ludwig, Thomas
Jin, Haofang
Abstract
Synergistic compositions for improving mineral bioaccessibility comprise lutein, casein phosphopeptide or 1,3-dioleoyl-2-palmitoylglycerol, preferably in combination with one or more of non-digestible oligosaccharides. The compositions can be used to prevent and/or treat mineral deficiency and associated conditions, preferably anaemia, said mineral comprises iron and/or calcium.
The invention relates to a nutritional composition comprising a combination of (i) co-enzyme Q10 with (ii) vitamin D and (iii) vitamin B2, for use in the treatment of stroke, preferably ischemic stroke. The invention also relates to a composition comprising a combination of co-enzyme Q10 and vitamin D, and vitamin D3 with optionally polyunsaturated fatty acids selected from DHA, EPA and/or DPA; and/or choline, choline salts and/or choline esters.
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/375 - Ascorbic acid, i.e. vitamin C; Salts thereof
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/455 - Nicotinic acid, i.e. niacin; Derivatives thereof, e.g. esters, amides
A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
A61K 33/04 - Sulfur, selenium or tellurium; Compounds thereof
A61K 33/06 - Aluminium, calcium or magnesium; Compounds thereof
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
72.
NUTRITIONAL COMPOSITION FOR NEURODEGENERATION AND NEUROTRAUMA
The invention relates to a nutritional composition comprising a combination of (i) omega-3 fatty acid DHA with (ii) vitamin B2 and (iii) vitamin D3 for use in the treatment of neurodegenerative diseases and/or neurotrauma. The invention also relates to a composition comprising a combination of DHA, vitamin B2, vitamin D3 with optionally one or more from (iv) choline or a salt thereof and/or choline esters; and (v) dietary fibres and/or dietary butyrate.
A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/375 - Ascorbic acid, i.e. vitamin C; Salts thereof
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
A61K 33/04 - Sulfur, selenium or tellurium; Compounds thereof
A61K 33/06 - Aluminium, calcium or magnesium; Compounds thereof
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
73.
LUTEIN FOR USE IN INHIBITING MAST CELL DEGRANULATION
NUTRICIA EARLY LIFE NUTRITION (SHANGHAI) CO., LTD. (China)
Inventor
Knipping, Catharina Theresia
Garssen, Johan
Ludwig, Thomas
Buurman, Nicole
Jin, Haofang
Abstract
It relates to nutritional compositions comprising lutein for inhibiting mast cell degranulation, thereby preventing or treating symptoms or disorders associated with mast cell degranulation. Preferably, the compositions comprise lutein and non-digestible carbohydrates, such as those selected from prebiotic oligosaccharides, human oligosaccharides and combinations thereof.
A nutritional composition comprising digestible carbohydrates, protein and lipid, wherein the lipid comprises phospholipids, for use in improving the cognitive development in an infant born to a mother with hyperglycemia during pregnancy.
The invention concerns a native whey protein composition with profound amounts of native whey protein and with beta-casein for use in the treatment and/or prevention of gastrointestinal intolerance. The inventors found that the native whey protein composition relatively high in beta-casein and low in kappa- and alpha-casein provides a beneficial effect on gastrointestinal intolerance.
A23C 21/06 - Mixtures of whey with milk products or milk components
A23C 9/142 - Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
NUTRICIA EARLY LIFE NUTRITION (SHANGHAI) CO., LTD. (China)
Inventor
Wopereis, Harm Johannes
Roeselers, Guus
Liu, Mengjin
Jin, Yi
Abstract
The invention pertains to a composition for use in increasing the relative abundance of Bacteroides and Parabacteroides in the intestinal microbiota of an infant that was delivered by Caesarean section or of an infant that was exposed to antibiotics early in life (e.g. intrapartum antibiotic prophylaxis (IAP) ), preferably an infant that was delivered by Caesarean section, wherein the composition comprises Bifidobacterium breve and non‐digestible oligosaccharide (s).
The invention relates to a nutritional composition selected from infant milk formulation, follow-on milk formulation and growing-up milk formulation for use in preventing or reducing programmed obesity after early childhood in female subjects that are overfed during infancy, wherein the nutritional composition comprises phospholipids, sphingolipids and cholesterol.
The present invention relates to formulae for infants comprising large lipid globules and/or lipid globules with a coating of phospholipids for controlling and reducing blood pressure in childhood.
Described is a feeding device, feeding system and method for determining a location of a feeding tube. In particular, the invention relates to a feeding device and method determining a location of a distal end of the feeding tube based on a pressure correlation between respective pressures measured by a distal end pressure sensor and another pressure sensor located further to a proximal end of the tube.
A card based container has a tubular sidewall of laminate material and first and second end closures, sealed to the tubular sidewall to form a hermetically sealed package. The sidewall comprises an outer card layer, an inner hygienic layer and one or more sealing strips provided at an inner surface of the inner hygienic layer, located at connection locations where the sidewall seals to itself or to the respective end closures. The sealing strips comprises a heat-sealable polymer. The overall amount of non-paper content in the sidewall and in the package may thus be reduced.
B65D 3/10 - Rigid or semi-rigid containers having bodies or peripheral walls of curved or partially-curved cross-section made by winding or bending paper without folding along defined lines characterised by form of integral or permanently- secured end closure
B65D 3/26 - Opening arrangements or devices incorporated in, or attached to, containers
B65D 51/20 - Caps, lids, or covers co-operating with an inner closure arranged to be opened by piercing, cutting, or tearing
B65D 77/20 - Container closures formed after filling by applying separate lids or covers
A card based container has a tubular sidewall of laminate material and first and second end closures, sealed to the tubular sidewall to form a hermetically sealed package. The sidewall comprises an outer card layer, an inner hygienic layer and one or more sealing strips provided at an inner surface of the inner hygienic layer, located at connection locations where the sidewall seals to itself or to the respective end closures. The sealing strips comprises a heat-sealable polymer. The overall amount of non-paper content in the sidewall and in the package may thus be reduced.
B65D 3/10 - Rigid or semi-rigid containers having bodies or peripheral walls of curved or partially-curved cross-section made by winding or bending paper without folding along defined lines characterised by form of integral or permanently- secured end closure
B65D 3/26 - Opening arrangements or devices incorporated in, or attached to, containers
B65D 51/20 - Caps, lids, or covers co-operating with an inner closure arranged to be opened by piercing, cutting, or tearing
B65D 77/20 - Container closures formed after filling by applying separate lids or covers
The invention pertains to a nutritional composition comprising therapeutically effective amounts of a combination of (a) hydrolysed whey protein and (b) MCT for use in (i) reducing tumor growth and/or (ii) for use in improving treatment efficacy in a subject having cancer and undergoing cancer treatment.
The invention provides a method, system, and computer program product for determining a maturation state of an infant aged between 0 and 120 months, comprising: measuring at least one microbial biomarker from a set of measurable microbial biomarkers from a faecal sample of the infant; determining a predicted age of the infant based on the at least one microbial biomarker; wherein the at least one microbial biomarker is selected from the set of measurable microbial biomarkers based on an analysis of the set of measurable microbial biomarkers as measured in faecal samples from a plurality of vaginally-born breast-fed infants at a plurality of ages, the predicted age is obtained based on an evaluation of the at least one measured microbial biomarker using a function based on a plurality of corresponding at least one biomarkers measured in the faecal samples from the plurality of vaginally-born breast-fed infants at the plurality of ages.
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
The invention relates to a first composition providing at least one of acetic acid or butyric acid for controlling ketosis associated with a ketogenic diet in a subject adhering to a ketogenic diet, wherein controlling ketosis involves a) administering the first composition, b) optionally administering a second composition comprising propionic acid to reduce ketone production/ administering a second composition comprising propionic acid provided that blood ketone levels are above (3) mmol/L.
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present invention relates to propionic acid for decreasing ketone production and/or preventing and/or treating ketoacidosis in a human subject in need thereof and wherein said subject is administered therapeutically effective amounts of propionic acid, preferably in a range of 1 mg to 1200 mg propionic acid per day.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The invention relates to a neuroprotective composition comprising therapeutically effective amounts of a combination of pyruvate and citrate, for the treatment and/or prevention of neuronal damage in a subject suffering from or at risk of seizures.
The invention relates to at least one of C4 or C6 fatty acids and optionally C2 fatty acids for enhancing ketosis associated with a ketogenic diet and/or preventing and/or treating resistance to a ketogenic diet, in a subject adhering to a ketogenic diet, wherein the at least one of C4 or C6 fatty acids and optionally C2 fatty acids are comprised in a non-ketogenic ketogenic diet-booster composition, or the at least C4 or C6 fatty acids and optionally C2 fatty acids are provided in non-ketogenic amounts by a dietary fibre blend comprised in a non-ketogenic ketogenic diet-booster composition.
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A consortium of specific probiotic bacteria comprising Bifidobacterium bifidum and Bifidobacterium breve with specific carbohydrate degrading properties, specific human milk oligosaccharide and preferably also beta-galacto-oligosaccharides with a higher degree of polymerization, is particularly effective for improving intestinal microbiota resilience.
The present invention concerns a process for producing a dry cereal composition, comprising (a) fermenting phytic acid containing cereals by phytase-positive lactic acid bacteria at a temperature below 45° C., until a pH of at most 5.9 is reached, (b) heating the fermented cereals obtained in step (a) to a temperature in the range of 40-55° C., for a period of at least 1.5 h; (c) drying the fermented and phytase treated cereals originating from step (b) to obtain the dry cereal composition. The present invention is ideally suited to reduce the phytate content of fermented cereals, thereby increasing the bio-availability of minerals. The invention further contains the dry cereal composition obtainable by the process according to the invention, especially having a molar ratio of phytate to iron of at most 1, and the use thereof in increasing the bio-availability of minerals.
The invention concerns a process of preparing an allergenic, edible powder product suitable for introducing or reintroducing protein to a human subject allergic to the protein or at risk of becoming allergic to the protein, the process comprising: (a) providing a powder comprising protein and reducing sugar, wherein the powder comprises a milk protein comprising beta-lactoglobulin (BLG), preferably BLG-A; and (b) heating the powder of step (a) (homogeneously) within a heated, vibrating pipe, wherein the powder is heated at a temperature from 60 to 150 °C, preferably from 70 to 120 °C, more preferably from 70 to 100 °C, wherein the relative humidity (RH) within the pipe is controlled below 80%, to obtain a powder wherein the protein has been glycated with the reducing sugar; (c) optionally adding any heat-sensitive components and/or bulking agents to the powder after step (b), (d) packaging the powder, to obtain a packaged amount of an allergenic, edible powder: (i) having a (predetermined) antigenicity reduced at least 20% compared to the protein reference; and/or (ii) wherein the glycated protein has a (predetermined) degree of glycation of at least 5% expressed as the percentage of lysine residues that are blocked by the reducing sugar on BLG, preferably BLG-A, wherein the powder is preferably characterized by at least (ii).
A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
A23C 9/16 - Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
A23C 11/10 - Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins
Method for providing a container with food, the method comprising: providing a container for infant formula food, adding the food, sealing the container with a gas-tight membrane seal, adding an inner scannable code on the gas-tight membrane seal, closing the container with a tamper-proof closure means, so that the inner scannable code is not scannable without breaking a part of the tamper-proof closure means, and storing the inner scannable code in a database.
B65B 1/04 - Methods of, or means for, filling the material into the containers or receptacles
B65B 7/28 - Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
B65B 61/26 - Auxiliary devices, not otherwise provided for, for operating on sheets, blanks, webs, binding material, containers or packages for marking or coding completed packages
B65D 43/16 - Non-removable lids or covers hinged for upward or downward movement
B65D 51/20 - Caps, lids, or covers co-operating with an inner closure arranged to be opened by piercing, cutting, or tearing
B65D 51/24 - Closures not otherwise provided for combined with auxiliary devices for non-closing purposes
G06K 7/14 - Methods or arrangements for sensing record carriers by corpuscular radiation using light without selection of wavelength, e.g. sensing reflected white light
G06K 19/06 - Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
G06Q 10/0639 - Performance analysis of employees; Performance analysis of enterprise or organisation operations
94.
ELECTRONIC DEVICE AND METHOD FOR DETERMINING HUMAN HEIGHT USING NEURAL NETWORKS
Electronic device for estimating a height of a human, the electronic device comprising: a processor configured to: obtain an image including at least a part of a representation of the human and reference information; input the image to a first neural network and obtain as output from the first neural network first information, the first information related to a plurality of keypoints in the body of the human; input the image to a second neural network and obtain as output from the second neural network second information, the second information related to the reference information; and estimate the height of the human based on the first information and the second information; and an output unit configured to output the estimated height.
The invention pertains to a solid composition suitable for treating adult animals that suffer from brain-related disorders, brain-related decline or brain-related diseases, preferably suitable for treating adult animals that suffer from brain-related disorders, the composition containing (i) a uridine source, wherein the amount of the sum of all uridine sources, calculated on the basis of the weight of the molar equivalent of uridine monophosphate (UMP), is 0.3-15 g per 100 g dry weight of the composition, (ii) a polyunsaturated fatty acid, preferably an omega-3 polyunsaturated fatty acid, (iii) choline bitartrate, (iv) a buffering salt component, and (v) a milk protein source, wherein the milk protein source is a milk powder, and the buffering salt component containing at least one food approved salt, with a buffering capacity between pH 5 – 8, the buffering salt component preferably containing a mixture of food-approved salts, or a food-approved salt and its conjugated acid or base.
A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
96.
Formula with galactomannan gum and non digestible oligosaccharides
The present invention relates to anti-regurgitation formula with locust bean gum and non-digestible oligosaccharides for improved effect on functional gastro-intestinal disorders in infants and young children.
A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
A23L 29/244 - Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Dietetic food adapted for special medical purposes; dietetic foods and beverages and preparations adapted for medical purposes; food for babies; food for patients and sick persons in the nature of dietetic foods adapted for medical purposes; infant formula; food for babies with special nutritional needs; liquid and powdered non-dairy and plant-based milks for babies, namely, milks derived from plants, vegetables, cereals, grains, nuts, seeds, beans and fruits; nutritional products for medical purposes, namely, nutritionally fortified beverages; nutritional supplements; cereals for infants in the nature of food for babies; vitamin preparations; dietetic foods adapted for medical purposes for pregnant, lactating and breast feeding women; dietetic milk adapted for medical purposes for pregnant, lactating and breast feeding women; dietary fiber to aid digestion; protein dietary supplements; soy protein dietary supplements; protein supplements shakes; energy bars used as food supplements; dietary supplements for human beings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Dietetic food for special medical purposes; dietetic foods and substances adapted for medical purposes; food for babies; food for patients and sick persons in the nature of dietetic foods adapted for medical purposes; infant formula; food for babies with special nutritional needs; liquid and powdered non-dairy and plant-based milks for babies, namely, milks derived from plants, vegetables, cereals, grains, nuts, seeds, beans and fruits; nutritional products for medical purposes, namely, nutritionally fortified beverages; nutritional supplements; cereals for infants in the nature of food for babies; vitamin preparations; dietetic foods adapted for medical purposes for pregnant, lactating and breast feeding women; dietetic milk adapted for medical purposes for pregnant, lactating and breast feeding women; dietary fiber to aid digestion; protein dietary supplements; soy protein dietary supplements; protein supplements shakes; energy bars used as food supplements; dietary supplements for human beings
99.
NUTRITIONAL COMPOSITION FOR MUSCLE MASS, STRENGTH AND FUNCTION
The invention pertains to a nutritional composition for use in prevention and/or treatment of whole body protein metabolism decline or whole body protein function decline, or for therapeutic use in improving whole body protein metabolism or whole body protein function, in a human subject, wherein the human subject is preferably an ageing human elderly subject of at least 40 years of age, wherein the composition comprises a protein fraction comprising 32-58wt% pea protein, 30-56wt% soy protein and 8-16wt% free leucine, preferably a protein fraction comprising 36-54wt% pea protein, 34-52wt% soy protein and 10-14wt% free leucine, and optionally up to 5wt% of free branched chain amino acids other than leucine, based on all proteinaceous matter, wherein the composition is essentially free from animal protein.
The present invention relates to a use of octenylsuccinyl anhydride substituted starch (OSA starch) for increasing the dry weight content and/or the fat content of a liquid composition that is subjected to a spray-drying step, and also to a process for preparing powders. The present invention enables the spray-drying of emulsions that contain a high amount of fat. The present invention also relates to the powder products obtainable by the process and nutritional products such as an infant milk powder, grow up milk, toddler milk or as a medical nutritional product that can be formulated therewith.
A23L 29/219 - Chemically modified starch; Reaction or complexation products of starch with other chemicals
A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
A23P 10/47 - Making free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added using additives, e.g. emulsifiers, wetting agents or dust-binding agents
C11B 15/00 - Solidifying fatty oils, fats, or waxes by physical processes
